公开(公告)号：US10363265B2

公开(公告)日：2019-07-30

申请号：US13730669

申请日：2012-12-28

Applicant: Idenix Pharmaceuticals LLC ,  Universita Degli Studi Di Cagliari

Inventor： Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: A61K31/7072 ,  A61K31/7068 ,  A61K31/708 ,  C07H19/04 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  A61K31/7076 ,  A61K45/06 ,  A61K31/7056 ,  A61K38/21 ,  G03C1/005

Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

公开(公告)号：US10758557B2

公开(公告)日：2020-09-01

申请号：US16440659

申请日：2019-06-13

Applicant: Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari

Inventor： Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: A61K31/7076 ,  A61K31/708 ,  C07H19/04 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  A61K31/7056 ,  A61K38/21 ,  G03C1/005

Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

公开(公告)号：US20190290670A1

公开(公告)日：2019-09-26

申请号：US16440659

申请日：2019-06-13

Applicant: Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari

Inventor： Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: A61K31/708 ,  A61K38/21 ,  A61K31/7056 ,  C07H19/10 ,  C07H19/20 ,  C07H19/16 ,  A61K31/7068 ,  C07H19/06 ,  C07H19/04 ,  A61K45/06 ,  A61K31/7076 ,  A61K31/7072

Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

公开(公告)号：US20180235993A1

公开(公告)日：2018-08-23

申请号：US15952117

申请日：2018-04-12

Applicant: Idenix Pharmaceuticals LLC ,  Universita' degli Studi di Cagliari

Inventor： Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: A61K31/7072 ,  C07H19/20 ,  A61K38/21 ,  A61K31/7052 ,  A61K31/7056 ,  C07H19/16 ,  A61K31/7076 ,  C07H19/23 ,  C07H19/06 ,  C07H19/073 ,  C07H19/10 ,  A61K31/7064

CPC classification number: A61K31/7072 ,  A61K31/7052 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7076 ,  A61K38/21 ,  C07H19/06 ,  C07H19/073 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  C07H19/23 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389

Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

公开(公告)号：US10525072B2

公开(公告)日：2020-01-07

申请号：US14972009

申请日：2015-12-16

Applicant: Idenix Pharmaceuticals LLC ,  Universita Degli Studi Di Cagliari

Inventor： Jean-Pierre Sommadossi ,  Paolo La Colla ,  David N. Standring ,  Vadim Bichko ,  Lin Qu

IPC: C12Q1/70 ,  A61K31/7072 ,  A61K31/7052 ,  A61K38/21 ,  A61K45/06 ,  C07H19/06 ,  C07H19/16 ,  C07K14/005 ,  C12Q1/04 ,  C12Q1/18

Abstract: The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2′-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXSGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.

公开(公告)号：US20210024565A1

公开(公告)日：2021-01-28

申请号：US17061409

申请日：2020-10-01

Applicant: Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari ,  Centre National De La Recherche Scientifique ,  Universite de Montpellier

Inventor： Richard Storer ,  Gilles Gosselin ,  Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: C07H19/16 ,  A61K47/60 ,  A61K31/675 ,  A61K31/7072 ,  A61K31/7076 ,  A61K38/21 ,  A61K45/06 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/22 ,  A61K31/7068 ,  A61K31/708 ,  C07H19/056 ,  C07H19/06 ,  A61K31/7056 ,  A61K9/20 ,  A61K9/48

Abstract: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

公开(公告)号：US20180237467A1

公开(公告)日：2018-08-23

申请号：US15890990

申请日：2018-02-07

Applicant: Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari ,  Centre National De La Recherche Scientifique ,  Universite de Montpellier

Inventor： Richard Storer ,  Gilles Gosselin ,  Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: C07H19/16 ,  A61K31/7056 ,  A61K45/06 ,  C07H19/06 ,  C07H19/056 ,  A61K38/21 ,  A61K31/708 ,  A61K31/7068 ,  A61K47/60 ,  A61K9/48 ,  A61K9/20 ,  A61K31/675 ,  A61K31/7072 ,  A61K31/7076 ,  C07H19/22 ,  C07H19/048 ,  C07H19/04 ,  C07H19/00

CPC classification number: C07H19/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/60 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/056 ,  C07H19/06 ,  C07H19/22 ,  A61K2300/00

Abstract: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.